You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

nivolumab

( nye-VOL-ue-mab )
Funding:
New Drug Funding Program
  • Nivolumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
  • Nivolumab - Advanced or Metastatic Non-Small Cell Lung Cancer
  • Nivolumab - Advanced or Metastatic Renal Cell Carcinoma and No Prior mTOR Inhibitor
  • Nivolumab - Advanced or Metastatic Renal Cell Carcinoma and Prior mTOR Inhibitor
  • Nivolumab - Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck which is Platinum Resistant or Refractory
  • Nivolumab plus Ipilimumab - Advanced Melanoma (Unresectable or Metastatic Melanoma)
  • Nivolumab plus Ipilimumab – Metastatic Renal Cell Carcinoma
Other Name(s): Opdivo
Appearance: solution , mixed into larger bags of fluids

You might also be interested in